Inmazeb (Regeneron Pharmaceuticals) Market Research Report 2026: Epidemiology, Pipeline Analysis, Trends, Strategies, & Forecasts, 2020-2025, 2025-2030F, 2035F [Yahoo! Finance]
Regeneron Pharmaceuticals, Inc. (REGN)
Last regeneron pharmaceuticals, inc. earnings: 2/6 06:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.regeneron.com
Company Research
Source: Yahoo! Finance
Rising demand for Ebola treatments, government stockpiling, enhanced healthcare infrastructure, and drug access programs are driving growth, with North America as a major market and Asia-Pacific poised for rapid expansion. Dublin, March 10, 2026 (GLOBE NEWSWIRE) -- The "Inmazeb Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts" has been added to ResearchAndMarkets.com's offering. The Inmazeb market is experiencing notable growth due to several factors impacting both historic and forecast periods. The past growth was largely driven by high mortality rates from Ebola outbreaks and a global lack of effective treatment options, prompting accelerated regulatory approvals. In the forecast period, further expansion is expected as a result of enhanced outbreak preparedness, increased funding for infectious diseases, and superior surveillance systems. These advancements are paired with a rise in demand for Ebola therapeutics, robust government stockpiling, an
Show less
Read more
Impact Snapshot
Event Time:
REGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
REGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
REGN alerts
High impacting Regeneron Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
REGN
News
- Is Regeneron a Multimillionaire-Maker Stock? [Yahoo! Finance]Yahoo! Finance
- Regeneron to Report First Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on April 29, 2026GlobeNewswire
- Dupixent® (dupilumab) Approved in Japan as the First Targeted Medicine to Treat Adults with Bullous Pemphigoid (BP)GlobeNewswire
- How The Regeneron (REGN) Story Is Shifting As Dupixent And Pipeline Expectations Reset [Yahoo! Finance]Yahoo! Finance
- Is Regeneron Pharmaceuticals, Inc. (REGN) A Good Stock To Buy? [Yahoo! Finance]Yahoo! Finance
REGN
Earnings
- 1/30/26 - Beat
REGN
Sec Filings
- 3/27/26 - Form SCHEDULE
- 3/3/26 - Form 4
- 2/23/26 - Form 4
- REGN's page on the SEC website